Cholangioscopy With Spyglass DS Using Percutaneous Transhepatic Cholangiography Access
NCT ID: NCT06096129
Last Updated: 2023-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
22 participants
OBSERVATIONAL
2016-01-31
2022-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosis and Percutaneous Treatment of Biliary Tract Diseases
NCT06816615
Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions
NCT05600803
Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)
NCT01556555
Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy
NCT02967926
Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)
NCT02776709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Endoscopic retrograde pancreatography (ERCP) is the standard procedure for the treatment of biliary strictures1 and can be further supplemented with magnetic resonance cholangiopancreatography to increase diagnostic accuracy. However, ERCP is limited by its low diagnostic sensitivity6. Furthermore, some difficult strictures require direct visualization of the lesions with targeted biopsies. In such cases, peroral cholangioscopy (POCS) provides an alternative when traditional ERCP is not feasible. POCS can directly visualize target lesions, obtain targeted biopsies, and is shown to be safe and useful when diagnosing indeterminate biliary strictures1. However, some patients have previously undergone upper gastrointestinal surgery, which can alter both duodenal and biliary anatomy. Moreover, strictures caused by PSC may be multifocal and/or positioned over the biliary confluence, which can make visualization difficult2. Conventional ERCP and POCS are not feasible in these patients, and another approach is required7,8.
Percutaneous transhepatic cholangioscopy (PTCS) is an alternative, attractive procedure owing to a shorter and more straightforward route to all parts of the biliary tree. Studies have shown that PTCS is safe, effective, and feasible for the visualization of indeterminate biliary strictures and in cases with altered biliary anatomy7,9-12. In addition, the studies demonstrated high diagnostic accuracy of PTCS and reported a satisfactory rate of technical success7,9-12.
Despite these preliminary studies, literature concerning the feasibility of PTCS using SpyGlass DS technology (S-PTCS) remains sparse. This study aimed to evaluate the use, specifically the visual and histological success, and the specificity, sensitivity, and complication rate of S-PTCS during a 5-year period at a Danish tertiary referral center for upper gastrointestinal and hepato-pancreato-biliary surgery and transplantation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spy PTC
People who had Spy PTC performed
Spy PTC
Percutaneous transhepatic cholangioscopy with SpyGlass DS system
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spy PTC
Percutaneous transhepatic cholangioscopy with SpyGlass DS system
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Trygve Ulvund Solstad
MD (Medical Doctor)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael P Achiam, MD, Ph.D
Role: STUDY_DIRECTOR
Rigshospitalet, Denmark
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R-21069569
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.